Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trifarotene - Galderma/Mayne Pharma

Drug Profile

Trifarotene - Galderma/Mayne Pharma

Alternative Names: AKLIEF; CD-5789

Latest Information Update: 05 Feb 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galderma
  • Developer Galderma; Mayne Pharma Group
  • Class Antiacnes; Antineoplastics; Benzoic acids; Keratolytics; Pyrrolidines; Retinoids; Skin disorder therapies; Small molecules
  • Mechanism of Action Retinoic acid receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ichthyosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne vulgaris
  • Phase II Ichthyosis
  • No development reported Cutaneous T-cell lymphoma

Most Recent Events

  • 18 Jan 2021 Registered for Acne vulgaris (In adolescents, In children, In adults) in Australia (Topical, Cream)
  • 23 Dec 2019 Galderma completes a phase III trial in Acne vulgaris (In children, In adolescents, In adults) in USA (NCT03915860)
  • 20 Dec 2019 Galderma anticipates the national marketing authorisations across concerned European member states in 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top